🇺🇸 S (+) Ketamine in United States

24 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 24

Most-reported reactions

1. Drug Ineffective — 5 reports (20.83%)
2. Cardiac Arrest — 3 reports (12.5%)
3. Abdominal Distension — 2 reports (8.33%)
4. Anaemia — 2 reports (8.33%)
5. Anaphylactic Reaction — 2 reports (8.33%)
6. Blood Count Abnormal — 2 reports (8.33%)
7. Coagulopathy — 2 reports (8.33%)
8. Completed Suicide — 2 reports (8.33%)
9. Drug Interaction — 2 reports (8.33%)
10. Dysphonia — 2 reports (8.33%)

Source database →

Frequently asked questions

Is S (+) Ketamine approved in United States?

S (+) Ketamine does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for S (+) Ketamine in United States?

Asker & Baerum Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.